Differential effects of insulin on peripheral diabetes-related changes in mitochondrial bioenergetics: Involvement of advanced glycosylated end products

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 11, 2011, Pages 1460-1471

  Remor, Aline Pertile ^a   de Matos, Filipe José ^a   Ghisoni, Karina ^a   da Silva, Thiago Lenoir ^a   Eidt, Greici ^a   Búrigo, Marília ^a   de Bem, Andreza Fabro ^a   Silveira, Paulo César Lock ^a   de León, Andrés ^b   Sanchez, Maria Cecilia ^c   Hohl, Alexandre ^a   Glaser, Viviane ^a   Gonçalves, Carlos Alberto ^d   Quincozes Santos, André ^d   Borba Rosa, Rafael ^e   Latini, Alexandra ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

^c UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e UNIVERSIDADE DO VALE DO RIO DOS SINOS   (Brazil)

Author keywords

Cardioprotection; Hyperglycemia; Insulin; Mitochondrial oxidative stress; Streptozotocin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYTOCHROME C OXIDASE; DNA; GLUCOSE; INSULIN; METHYLGLYOXAL; MITOCHONDRIAL ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); STREPTOZOCIN; SUCCINATE DEHYDROGENASE (UBIQUINONE);

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENERGY METABOLISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLYCATION; HEART; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN TREATMENT; KIDNEY; LIVER; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN; SKELETAL MUSCLE; SKIN FIBROBLAST; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CELLS, CULTURED; DIABETES MELLITUS; ELECTRON TRANSPORT; ENERGY METABOLISM; FIBROBLASTS; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; INSULIN; MALE; MIDDLE AGED; MITOCHONDRIA; MUSCLE, SKELETAL; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PYRUVALDEHYDE; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SKIN; STREPTOZOCIN;

ANIMALIA; RATTUS;

EID: 80053460459     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.06.017     Document Type: Article

References (67)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. American Diabetes Association Standards of medical care in diabetes - 2010. Diabetes Care 2010, 33(Suppl 1):S11-S61.
3. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
4. Boulton A.J., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., Malik R.A., Maser R.E., Sosenko J.M., Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956-962.
5. Vinik A.I., Maser R.E., Mitchell B.D., Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553-1579.
6. Camici P.G., Crea F. Coronary microvascular dysfunction. N. Engl. J. Med. 2007, 356:830-840.
7. Wei M., Gaskill S.P., Haffner S.M., Stern M.P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998, 21:1167-1172.
8. Brem H., Sheehan P., Rosenberg H.J., Schneider J.S., Boulton A.J. Evidence-based protocol for diabetic foot ulcers. Plast. Reconstr. Surg. 2006, 117:193S-209S. (discussion 210S-211S).
9. Skyler J.S., Bergenstal R., Bonow R.O., Buse J., Deedwania P., Gale E.A., Howard B.V., Kirkman M.S., Kosiborod M., Reaven P., Sherwin R.S. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009, 119:351-357.
10. Feskens E.J., Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J. Clin. Epidemiol. 1992, 45:1327-1334.
11. Orchard T.J., Costacou T. When are type 1 diabetic patients at risk for cardiovascular disease?. Curr. Diab. Rep. 2010, 10:48-54.
12. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005, 353:2643-2653.
13. Diabetes The Control and Complications Trial Research Group, the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329:977-986.
14. Reichard P., Nilsson B.Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl. J. Med. 1993, 329:304-309.
15. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
16. Thornalley P.J., Langborg A., Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 1999, 344(Pt 1):109-116.
17. Beisswenger P.J., Makita Z., Curphey T.J., Moore L.L., Jean S., Brinck-Johnsen T., Bucala R., Vlassara H. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995, 44:824-829.
18. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., Lyons T.J. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest. 1993, 91:2470-2478.
19. Hammes H.P., Alt A., Niwa T., Clausen J.T., Bretzel R.G., Brownlee M., Schleicher E.D. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999, 42:728-736.
20. Bucala R., Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am. J. Kidney Dis. 1995, 26:875-888.
21. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 2004, 63:582-592.
22. Cooper M.E. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am. J. Hypertens. 2004, 17:31S-38S.
23. Petersen K.F., Dufour S., Befroy D., Garcia R., Shulman G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 2004, 350:664-671.
24. Rosca M.G., Mustata T.G., Kinter M.T., Ozdemir A.M., Kern T.S., Szweda L.I., Brownlee M., Monnier V.M., Weiss M.F. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am. J. Physiol. Renal Physiol. 2005, 289:F420-F430.
25. Kaji Y., Amano S., Usui T., Oshika T., Yamashiro K., Ishida S., Suzuki K., Tanaka S., Adamis A.P., Nagai R., Horiuchi S. Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest. Ophthalmol. Vis. Sci. 2003, 44:521-528.
26. Kasper M., Roehlecke C., Witt M., Fehrenbach H., Hofer A., Miyata T., Weigert C., Funk R.H., Schleicher E.D. Induction of apoptosis by glyoxal in human embryonic lung epithelial cell line L132. Am. J. Respir. Cell Mol. Biol. 2000, 23:485-491.
27. Denis U., Lecomte M., Paget C., Ruggiero D., Wiernsperger N., Lagarde M. Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction. Free Radic. Biol. Med. 2002, 33:236-247.
28. Romeo G., Liu W.H., Asnaghi V., Kern T.S., Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002, 51:2241-2248.
29. Kim J., Kim C.S., Sohn E., Jeong I.H., Kim H., Kim J.S. Involvement of advanced glycation end products, oxidative stress and nuclear factor-kappaB in the development of diabetic keratopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:529-536.
30. Latini A., da Silva C.G., Ferreira G.C., Schuck P.F., Scussiato K., Sarkis J.J., Dutra Filho C.S., Wyse A.T., Wannmacher C.M., Wajner M. Mitochondrial energy metabolism is markedly impaired by d-2-hydroxyglutaric acid in rat tissues. Mol. Genet. Metab. 2005, 86:188-199.
31. Keira S.M., Ferreira L.M., Gragnani A., Duarte I.d.S., Santos I.A.N.d. Experimental model for fibroblast culture. Acta Cir. Bras. 2004, 19(Suppl 1):11-16.
32. Westwood M.E., McLellan A.C., Thornalley P.J. Receptor-mediated endocytic uptake of methylglyoxal-modified serum albumin. Competition with advanced glycation end product-modified serum albumin at the advanced glycation end product receptor. J. Biol. Chem. 1994, 269:32293-32298.
33. Habeeb A.F. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal. Biochem. 1966, 14:328-336.
34. Biemel K.M., Reihl O., Conrad J., Lederer M.O. Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes: unraveling the structure of a pentosidine precursor. J. Biol. Chem. 2001, 276:23405-23412.
35. Reznick A.Z., Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 1994, 233:357-363.
36. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
37. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
38. Cassina A., Radi R. Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch. Biochem. Biophys. 1996, 328:309-316.
39. Fischer J.C., Ruitenbeek W., Berden J.A., Trijbels J.M., Veerkamp J.H., Stadhouders A.M., Sengers R.C., Janssen A.J. Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clin. Chim. Acta 1985, 153:23-36.
40. Schapira A.H., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., Clark J.B., Marsden C.D. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 1990, 55:2142-2145.
41. Rustin P., Chretien D., Bourgeron T., Gerard B., Rotig A., Saudubray J.M., Munnich A. Biochemical and molecular investigations in respiratory chain deficiencies. Clin. Chim. Acta 1994, 228:35-51.
42. Hutter E., Renner K., Pfister G., Stockl P., Jansen-Durr P., Gnaiger E. Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts. Biochem. J. 2004, 380:919-928.
43. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev. 2001, 17:189-212.
44. West I.C. Radicals and oxidative stress in diabetes. Diabet. Med. 2000, 17:171-180.
45. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I., Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
46. Du X.L., Edelstein D., Rossetti L., Fantus I.G., Goldberg H., Ziyadeh F., Wu J., Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12222-12226.
47. Boveris A., Cadenas E., Stoppani A.O. Role of ubiquinone in the mitochondrial generation of hydrogen peroxide. Biochem. J. 1976, 156:435-444.
48. Chen Q., Vazquez E.J., Moghaddas S., Hoppel C.L., Lesnefsky E.J. Production of reactive oxygen species by mitochondria: central role of complex III. J. Biol. Chem. 2003, 278:36027-36031.
49. Turrens J.F. Superoxide production by the mitochondrial respiratory chain. Biosci. Rep. 1997, 17:3-8.
50. Turrens J.F., Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem. J. 1980, 191:421-427.
51. Chinopoulos C., Adam-Vizi V. Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: relevance to Parkinson's disease. J. Neurochem. 2001, 76:302-306.
52. El-Osta A., Brasacchio D., Yao D., Pocai A., Jones P.L., Roeder R.G., Cooper M.E., Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 2008, 205:2409-2417.
53. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., Laurila E., Houstis N., Daly M.J., Patterson N., Mesirov J.P., Golub T.R., Tamayo P., Spiegelman B., Lander E.S., Hirschhorn J.N., Altshuler D., Groop L.C. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
54. Scarpulla R.C. Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. Gene 2002, 286:81-89.
55. Garnier A., Fortin D., Delomenie C., Momken I., Veksler V., Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J. Physiol. 2003, 551:491-501.
56. Puigserver P., Spiegelman B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev. 2003, 24:78-90.
57. Gugliucci A. "Blinding" of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance?. Med. Hypotheses 2009, 73:921-924.
58. Aizzat O., Yap S.W., Sopiah H., Madiha M.M., Hazreen M., Shailah A., Wan J.W., Nur S.A., Srjit D., Musalmah M., Yasmin A.M. Modulation of oxidative stress by Chorella vulgaris in streptozotocin (STZ) induced diabetic Sprague-Dawley rats. Adv. Med. Sci. 2010, 55:281-288.
59. Kamper M., Tsimpoukidi O., Chatzigeorgiou A., Lymberi M., Kamper E.F. The antioxidant effect of antiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Transl. Res. 2010, 156:26-36.
60. Lupachyk S., Shevalye H., Maksimchyk Y., Drel V.R., Obrosova I.G. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic. Biol. Med. 2011, 50:1400-1409.
61. Hipkiss A.R. Glycation, ageing and carnosine: are carnivorous diets beneficial?. Mech. Ageing Dev. 2005, 126:1034-1039.
62. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 2008, 415:333-344.
63. Teshima Y., Takahashi N., Thuc L.C., Nishio S., Nagano-Torigoe Y., Miyazaki H., Ezaki K., Yufu K., Hara M., Nakagawa M., Saikawa T. High-glucose condition reduces cardioprotective effects of insulin against mechanical stress-induced cell injury. Life Sci. 2010, 87:154-161.
64. Haluzik M., Nedvidkova J. The role of nitric oxide in the development of streptozotocin-induced diabetes mellitus: experimental and clinical implications. Physiol. Res. 2000, 49(Suppl 1):S37-S42.
65. Coughlan M.T., Thorburn D.R., Penfold S.A., Laskowski A., Harcourt B.E., Sourris K.C., Tan A.L., Fukami K., Thallas-Bonke V., Nawroth P.P., Brownlee M., Bierhaus A., Cooper M.E., Forbes J.M. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 2009, 20:742-752.
66. Cai W., He J.C., Zhu L., Lu C., Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13801-13806.
67. Phielix E., Schrauwen-Hinderling V.B., Mensink M., Lenaers E., Meex R., Hoeks J., Kooi M.E., Moonen-Kornips E., Sels J.P., Hesselink M.K., Schrauwen P. Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes 2008, 57:2943-2949.